Revance Therapeutics News

Revance Therapeutics | 8-K: Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

May 9 16:16 ET

Revance Therapeutics | 8-K: Current report

May 3 16:07 ET

Revance Therapeutics | DEFA14A: Others

Mar 21 16:13 ET

Revance Therapeutics | DEF 14A: Definitive information statements

Mar 21 16:12 ET

Revance Therapeutics | 8-K: Current report

Mar 5 17:09 ET

Revance Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Feb 29 13:28 ET

Revance Therapeutics | 8-K: Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

Feb 28 16:15 ET

Revance Therapeutics | 8-K: Current report

Feb 13 16:33 ET

Revance Therapeutics | 8-K: Current report

Feb 6 16:11 ET

Revance Therapeutics | 8-K: Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

Jan 8 00:00 ET

Revance Therapeutics | 8-K: Current report

Dec 15, 2023 16:04 ET

Revance Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers

Nov 14, 2023 16:22 ET

Revance Therapeutics | 8-K: Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update

Nov 8, 2023 16:09 ET

Revance Therapeutics | 8-K: Current report

Sep 19, 2023 09:01 ET

Revance Therapeutics | 8-K: Current report

Aug 30, 2023 19:20 ET

Revance Therapeutics | 8-K: Current report

Aug 14, 2023 08:02 ET

Revance Therapeutics | 8-K: Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update

Aug 8, 2023 16:08 ET

Revance Therapeutics | 8-K: Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update

May 9, 2023 16:07 ET

Revance Therapeutics | 8-K: Current report

May 8, 2023 16:08 ET

Revance Therapeutics | 8-K: Current report

Apr 19, 2023 16:06 ET